451 related articles for article (PubMed ID: 25140584)
1. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski JA; Zhou C; Winters KJ; Lachno DR; Howard J; Payne CD; Mant T; Jurcevic S; Frelinger AL
Platelets; 2015; 26(5):474-9. PubMed ID: 25140584
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Jakubowski JA; Zhou C; Jurcevic S; Winters KJ; Lachno DR; Frelinger AL; Gupta N; Howard J; Payne CD; Mant TG
Thromb Res; 2014 Feb; 133(2):190-5. PubMed ID: 24368019
[TBL] [Abstract][Full Text] [Related]
3. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
[TBL] [Abstract][Full Text] [Related]
4. Platelet activation and inhibition in sickle cell disease (pains) study.
Frelinger AL; Jakubowski JA; Brooks JK; Carmichael SL; Berny-Lang MA; Barnard MR; Heeney MM; Michelson AD
Platelets; 2014; 25(1):27-35. PubMed ID: 23469943
[TBL] [Abstract][Full Text] [Related]
5. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.
Polanowska-Grabowska R; Wallace K; Field JJ; Chen L; Marshall MA; Figler R; Gear AR; Linden J
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2392-9. PubMed ID: 21071696
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Wagner H; Lood C; Borna C; Gidlöf O; Truedsson L; Brown P; Zhou C; Winters K; Jakubowski JA; Erlinge D
J Thromb Thrombolysis; 2016 Oct; 42(3):369-75. PubMed ID: 27165280
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Jakubowski JA; Zhou C; Small DS; Winters KJ; Lachno DR; Frelinger AL; Howard J; Mant TG; Jurcevic S; Payne CD
Br J Clin Pharmacol; 2013 Jun; 75(6):1433-44. PubMed ID: 23171128
[TBL] [Abstract][Full Text] [Related]
9. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
[TBL] [Abstract][Full Text] [Related]
10. Increased platelet activation in subjects chronically exposed to cadmium: A pilot study.
Nontarach A; Srihirun S; Chaturapanich G; Unchern S; Swaddiwudhipong W; Pattanapanyasat K; Chamchoi A; Vivithanaporn P; Visoottiviseth P; Sibmooh N
Platelets; 2016; 27(2):136-42. PubMed ID: 26023812
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N; Rees DC
Expert Opin Investig Drugs; 2017 Jul; 26(7):865-872. PubMed ID: 28562105
[TBL] [Abstract][Full Text] [Related]
12. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
[TBL] [Abstract][Full Text] [Related]
13. Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor.
Siller-Matula JM; Akca B; Neunteufl T; Maurer G; Lang IM; Kreiner G; Berger R; Delle-Karth G
Platelets; 2016 Jun; 27(4):373-7. PubMed ID: 26555925
[TBL] [Abstract][Full Text] [Related]
14. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities.
Frelinger AL; Jakubowski JA; Li Y; Barnard MR; Linden MD; Tarnow I; Fox ML; Sugidachi A; Winters KJ; Furman MI; Michelson AD
J Thromb Haemost; 2008 Feb; 6(2):359-65. PubMed ID: 18021304
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
Graff J; Harder S; Wahl O; Scheuermann EH; Gossmann J
Clin Pharmacol Ther; 2005 Nov; 78(5):468-76. PubMed ID: 16321613
[TBL] [Abstract][Full Text] [Related]
16. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
Scholz T; Zhao L; Temmler U; Bath P; Heptinstall S; Lösche W
Platelets; 2002 Nov; 13(7):401-6. PubMed ID: 12487787
[TBL] [Abstract][Full Text] [Related]
17. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease.
Wun T; Soulieres D; Frelinger AL; Krishnamurti L; Novelli EM; Kutlar A; Ataga KI; Knupp CL; McMahon LE; Strouse JJ; Zhou C; Heath LE; Nwachuku CE; Jakubowski JA; Riesmeyer JS; Winters KJ
J Hematol Oncol; 2013 Feb; 6():17. PubMed ID: 23414938
[TBL] [Abstract][Full Text] [Related]
19. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
[TBL] [Abstract][Full Text] [Related]
20. P-selectin, tissue factor and CD40 ligand expression on platelet-leucocyte conjugates in the presence of a GPIIb/IIIa antagonist.
Zhao L; Bath PM; May J; Lösche W; Heptinstall S
Platelets; 2003; 14(7-8):473-80. PubMed ID: 14713516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
